Pharmacology of mixed NOP/mu ligands

L Toll, T V Khroyan, W E Polgar, Stephen M Husbands, N T Zaveri

Research output: Chapter or section in a book/report/conference proceedingChapter or section

3 Citations (SciVal)


The orvinols, including buprenorphine, emerged from research carried out by Reckitt and Colman in the 1960s and 1970s. Regulatory approval of buprenorphine for the treatment of opioid addiction has been a major success and has ultimately led, in part, to its analgesic activity now being fully exploited. As buprenorphine’s unique clinical profile is documented, efforts continue to rationalise this activity through understanding of its receptor pharmacology. This has included the development of new orvinols with mixed mu and kappa opioid receptor agonist activity and others with efficacy at mu and NOP receptors, the latter of particular interest for the development of new analgesics. Orvinols with mu and kappa antagonist activity, coupled with NOP receptor partial agonism have also been developed and have potential for the treatment of polydrug abuse.
Original languageEnglish
Title of host publicationResearch and Development of Opioid-Related Ligands
EditorsMei-Chuan Ko, Stephen M Husbands
Place of PublicationWashington, DC
PublisherAmerican Chemical Society
ISBN (Electronic)9780841227835
ISBN (Print)9780841227828
Publication statusPublished - 2013

Publication series

NameACS Symposium Series
PublisherAmerican Chemical Society


Dive into the research topics of 'Pharmacology of mixed NOP/mu ligands'. Together they form a unique fingerprint.

Cite this